Stock Code


Shanghai, China——On September 30, 2019, Shanghai Science and Technology Commission published a publicity list of the results of the evaluation of Shanghai innovative biomedical products in 2018-2019. And Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ Stent Graft System”) independently developed by Shanghai MicroPort Endovascular MedTech Co., Ltd (“Endovasctec™”) was successfully selected. Minos™ Stent Graft System was Approved special medical device approval process in 2017, gained NMPA approval in March and CE certificate in September 2019. And its post-marketing clinical study was selected for the 2019 “Science and Technology Innovation Action Plan” project in the field of cooperation between industry, education, research and medicine in Shanghai.

In order to accelerate the construction of a globally influential science and technology innovation center, and implement the Action Plan for Promoting the High Quality Development of Shanghai Biomedical Industry (2018-2020), Shanghai Science and Technology Commission organized evaluation of Shanghai innovative biomedical products in 2018-2019. A total of 46 products entered the publicity list.

As a new generation of abdominal aortic stent graft system independently developed by Endovasctec™,  Minos™ Stent Graft System, which is designed for endovascular aneurysm repair (EVAR) to treat abdominal aortic aneurysm with proximal neck length no less than 15mm. It is the only domestic product with the independent intellectual property right and reduces the outer diameter of the sheath to 14F (less than 5mm), which significantly reduces the vascular access requirement of Endovascular Aneurysm Repair. And it provides a better solution for patients with the complex abdominal aortic anatomy, especially for the patients with more access to the arterial stenosis.

In the future, Endovasctec™ will continue to adhere to the concept of continuous innovation, and devoted to creating more high-quality, innovative high-end medical device products, and accelerate the development of domestic medical device industry to high-end, intelligent and international development, thus provide patients with aortic and peripheral vascular diseases all over the world a more comprehensive and optimal inclusive medical solutions.